Figure 2From: NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver diseaseChanges of serum alanine aminotransferase (ALT) and LDL-cholesterol (LDL-C) levels during ezetimibe treatment. Decrease (%) from baseline is presented at 6 and 12 months after the treatment initiation. *p < 0.05 compared with baseline.Back to article page